MX354020B - Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer. - Google Patents
Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX354020B MX354020B MX2014011992A MX2014011992A MX354020B MX 354020 B MX354020 B MX 354020B MX 2014011992 A MX2014011992 A MX 2014011992A MX 2014011992 A MX2014011992 A MX 2014011992A MX 354020 B MX354020 B MX 354020B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- alzheimer
- treatment
- receptor antagonist
- ulfonamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Esta descripción se refiere a métodos de uso de la 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3 ,4-tetrahidroisoquinolina-7-sulfonamida en una terapia modificadora de la enfermedad para la enfermedad de Alzheimer, otras taupatías y enfermedades neurodegenerativas relacionadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305415.7A EP2647377A1 (en) | 2012-04-06 | 2012-04-06 | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
US201361792635P | 2013-03-15 | 2013-03-15 | |
PCT/EP2013/057241 WO2013150150A1 (en) | 2012-04-06 | 2013-04-05 | An h3 receptor antagonist for use in the treatment of alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014011992A MX2014011992A (es) | 2015-05-08 |
MX354020B true MX354020B (es) | 2018-02-08 |
Family
ID=46001073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014011992A MX354020B (es) | 2012-04-06 | 2013-04-05 | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20150031893A1 (es) |
EP (2) | EP2647377A1 (es) |
JP (1) | JP6143842B2 (es) |
KR (1) | KR20150000490A (es) |
CN (1) | CN104363911A (es) |
AR (1) | AR090605A1 (es) |
AU (1) | AU2013244928B2 (es) |
BR (1) | BR112014024736A2 (es) |
CA (1) | CA2868481A1 (es) |
ES (1) | ES2618924T3 (es) |
MX (1) | MX354020B (es) |
PL (1) | PL2833887T3 (es) |
RU (1) | RU2014144615A (es) |
SG (2) | SG10201801200PA (es) |
TW (1) | TW201402119A (es) |
UY (1) | UY34734A (es) |
WO (1) | WO2013150150A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
WO2015032966A1 (en) * | 2013-09-09 | 2015-03-12 | Sanofi | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
CN114053289B (zh) * | 2020-08-06 | 2023-06-27 | 北京箭牧科技有限公司 | 瑞德西韦在制备预防和治疗神经系统退行性疾病药物中的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
JP2006512404A (ja) | 2002-10-22 | 2006-04-13 | グラクソ グループ リミテッド | H3受容体リガンドとしてのアリールオキシアルキルアミン誘導体 |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
NZ540148A (en) | 2002-12-20 | 2007-11-30 | Glaxo Group Ltd | Benzazepine derivatives for the treatment of neurological disorders |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20060293298A1 (en) | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
EP1615909B1 (en) | 2003-04-23 | 2008-07-23 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
US20060247227A1 (en) | 2003-07-18 | 2006-11-02 | Bailey James M | Substituted piperidines as histamine h3 receptor ligands |
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
SI1751111T1 (sl) | 2004-03-01 | 2015-04-30 | Actelion Pharmaceuticals Ltd. | Substituirani 1,2,3,4-tetrahidroizokinolinski derivati |
GB0408083D0 (en) | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
JP2008502644A (ja) | 2004-06-18 | 2008-01-31 | グラクソ グループ リミテッド | ヒスタミンh3アンタゴニストとしての3−シクロアルキルベンズアゼピン |
GB0418267D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
SI1802307T1 (sl) | 2004-10-15 | 2008-08-31 | Glaxo Group Ltd | Derivati pirolidina kot ligandi histaminskih receptorjev |
RU2007125648A (ru) | 2004-12-07 | 2009-01-20 | Глэксо Груп Лимитед (GB) | Инденильные производные и их применение для лечения неврологических расстройств |
JP2008533117A (ja) | 2005-03-14 | 2008-08-21 | グラクソ グループ リミテッド | ヒスタミンh3受容体に対して親和性を有する縮合チアゾール誘導体 |
GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
EP1790646A1 (fr) | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
US20100120747A1 (en) | 2006-06-23 | 2010-05-13 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
CL2008000597A1 (es) | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
ATE554081T1 (de) | 2007-09-06 | 2012-05-15 | Glaxo Group Ltd | Piperazinderivate mit affinität zum histamin-h3- rezeptor |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
US20110189280A1 (en) | 2008-08-29 | 2011-08-04 | Allan James Clarke | Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof |
WO2010026113A1 (en) * | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
EP2445899B1 (en) | 2009-06-26 | 2016-05-11 | Sanofi | Novel fumarate salts of a histamine h3 receptor antagonist |
TW201118099A (en) | 2009-08-12 | 2011-06-01 | Boehringer Ingelheim Int | New compounds for the treatment of CNS disorders |
WO2011051423A1 (en) | 2009-11-02 | 2011-05-05 | Glaxo Group Limited | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
FR2976286B1 (fr) | 2011-06-08 | 2013-05-24 | Servier Lab | 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
EP2745876A1 (en) | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
WO2015032966A1 (en) * | 2013-09-09 | 2015-03-12 | Sanofi | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
-
2012
- 2012-04-06 EP EP12305415.7A patent/EP2647377A1/en not_active Ceased
-
2013
- 2013-04-03 TW TW102112006A patent/TW201402119A/zh unknown
- 2013-04-04 AR ARP130101105A patent/AR090605A1/es unknown
- 2013-04-05 RU RU2014144615A patent/RU2014144615A/ru unknown
- 2013-04-05 SG SG10201801200PA patent/SG10201801200PA/en unknown
- 2013-04-05 WO PCT/EP2013/057241 patent/WO2013150150A1/en active Application Filing
- 2013-04-05 ES ES13714652.8T patent/ES2618924T3/es active Active
- 2013-04-05 KR KR1020147029735A patent/KR20150000490A/ko not_active Application Discontinuation
- 2013-04-05 EP EP13714652.8A patent/EP2833887B1/en not_active Not-in-force
- 2013-04-05 BR BR112014024736A patent/BR112014024736A2/pt not_active IP Right Cessation
- 2013-04-05 UY UY0001034734A patent/UY34734A/es not_active Application Discontinuation
- 2013-04-05 CN CN201380029300.6A patent/CN104363911A/zh active Pending
- 2013-04-05 SG SG11201406093VA patent/SG11201406093VA/en unknown
- 2013-04-05 AU AU2013244928A patent/AU2013244928B2/en not_active Ceased
- 2013-04-05 CA CA2868481A patent/CA2868481A1/en not_active Abandoned
- 2013-04-05 MX MX2014011992A patent/MX354020B/es active IP Right Grant
- 2013-04-05 PL PL13714652T patent/PL2833887T3/pl unknown
- 2013-04-05 JP JP2015503896A patent/JP6143842B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-03 US US14/506,089 patent/US20150031893A1/en not_active Abandoned
-
2015
- 2015-10-01 US US14/872,812 patent/US9789102B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2868481A1 (en) | 2013-10-10 |
MX2014011992A (es) | 2015-05-08 |
US20160101099A1 (en) | 2016-04-14 |
UY34734A (es) | 2013-11-29 |
SG11201406093VA (en) | 2014-10-30 |
AU2013244928A1 (en) | 2014-10-30 |
ES2618924T3 (es) | 2017-06-22 |
KR20150000490A (ko) | 2015-01-02 |
US20150031893A1 (en) | 2015-01-29 |
EP2833887B1 (en) | 2016-12-28 |
TW201402119A (zh) | 2014-01-16 |
BR112014024736A2 (pt) | 2017-07-11 |
EP2833887A1 (en) | 2015-02-11 |
JP2015516963A (ja) | 2015-06-18 |
WO2013150150A1 (en) | 2013-10-10 |
AR090605A1 (es) | 2014-11-26 |
CN104363911A (zh) | 2015-02-18 |
EP2647377A1 (en) | 2013-10-09 |
JP6143842B2 (ja) | 2017-06-07 |
US9789102B2 (en) | 2017-10-17 |
SG10201801200PA (en) | 2018-04-27 |
RU2014144615A (ru) | 2016-05-27 |
AU2013244928B2 (en) | 2017-08-10 |
PL2833887T3 (pl) | 2017-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA027953B9 (ru) | АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ | |
CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
HK1246192A1 (zh) | 用於治療帕金森氏病的新治療方法 | |
ZA201402556B (en) | 8- carbamoyl- 2 - (2,3- di substituted pyrid - 6 -yl) - 1,2,3,4- tetrahydroisoquinoline derivatives as apoptosis- inducing agents for the treatment of cancer and immune and autoimmune diseases | |
IN2014DN07149A (es) | ||
IL226975B (en) | Low-dose pioglitazone for the diagnosis and treatment of Alzheimer's disease | |
MX2013007622A (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
MY164579A (en) | Safe and functional humanized antibodies | |
EP2811832A4 (en) | USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MORBUS CROHN AFTER FAILED PREVIOUS ANTI-TNF THERAPY | |
IL223819A0 (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
IN2014CN03597A (es) | ||
MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
IN2012DN05186A (es) | ||
SG11201601306QA (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
EP2967368A4 (en) | DEVICE AND METHOD FOR CALCULATING THE HEART TIME VOLUME OF A LIFE THROUGH APPLANATION TONOMETRY | |
IL260078B (en) | Therapy used to treat Gaucher disease | |
UA117154C2 (uk) | Антагоністи s1p3 | |
PH12015500012B1 (en) | Benzodioxole derivative and preparation method and use thereof | |
EP2946792A4 (en) | THERAPEUTIC AGENT AND THERAPY PROCEDURE WITH 1,25D3 MARRS FOR NEUROLOGICAL ILLNESSES SUCH AS MORBUS ALZHEIMER | |
MX354020B (es) | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer. | |
EP2829605A4 (en) | PROCESS FOR SCREENING THERAPEUTIC AND / OR PROPHYLACTICS FOR MORBUS ALZHEIMER | |
HK1220144A1 (zh) | -叔丁基-苄基 -氯- -氯- -乙基-苯基 -乙基 -氟- -三氟甲基-苯甲酰胺用於治療眼疾病的用途 | |
UA64530U (ru) | Способ лечения гиперестезии твердых тканей зубов у пациентов c гастроезофагеальной рефлюксной болезнью | |
EP2872633A4 (en) | CELL AND ANIMAL MODELS FOR THE SCREENING OF THERAPEUTIC ACTIVE SUBSTANCES FOR THE TREATMENT OF MORBUS ALZHEIMER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |